Movement Disorders Enrollment Form



Fax Referral To: 1-800-323-2445 Email Referral To: Customer.ServiceFax@CVSHealth.com

Phone: 1-866-215-9855

DATIENT INCORNATIO		mple Steps to S		ererrat		
PATIENT INFORMATION					0	Mala DE 1
Patient Name:			DOB:		Gender: [_]	Male Female
Preferred Contact Methods: Property Preferred Contact Methods: Property Pro	providing the phone nur bout your prescription(armacy will attempt to	mber(s) and email ad (s), account, and heal contact by phone.	ldress above, you Ith care. Standard	are consenting t I data rates apply	to receive automa y. Message freque	ated calls, emails and/or ency varies. If unable to
Primary Phone:			Alternate Phor	ne:		
	- None of Cost Circle					
Parent/Caregiver/Legal Guardiar			Relationship	o to patient		
PRESCRIBER INFORM	ATION					
Prescriber's Name:		Sta	ite License #:			
NPI #: DEA #: _	Gro	up or Hospital:				
Address: Phone:		C	City, State, ZIP C	Code:		
INSURANCE INFORMA s the Patient Insured?	No Is the Patient	enrolled or eligible	e for Medicare/I	Medicaid? 🗆	Yes □ No	
Medical Insurance:						
Prescription Insurance:						
Policy ID:	Group #	<i>‡</i> :	RX BIN #:	:	RX PCN #:	
☐ Check box if patient is enrolled	l in manufacturer co	pav assistance If	ves. please pro	vide ID#		
DIAGNOSIS AND CLIN			, , , ,			
leeds by Date:			□ Office □ Of	thor		
Diagnosis (ICD-10):		mp to ratient				
G24.01 Tardive Dyskinesia (TD G10 Huntington's Chorea (HD) G72.3 Periodic Paralysis Other Code: Description) n	-				
Allergies:		н	eight:in/c	cm	Weight:	lh/ka
PRESCRIPTION INFORMEDICATION		··	DOSE & DIR			QUANTITY/REFILI
	☐ 6 mg	Administer 6 n	Administer 6 mg by mouth twice a day. Increase dose by 6 Quantity: 30-day			
Austedo (initial prescription)	☐ 9 mg ☐ 12 mg	mg per day every week as needed to control symptoms. Maximum daily dose not to exceed 48 mg/day.			supply Refills: 0	
Austedo (maintenance prescription)	☐ 6 mg ☐ 9 mg ☐ 12 mg	Administer 6 mg by mouth twice a day. Increase dose by 6 mg per day every week as needed to control symptoms. Maximum daily dose not to exceed 48 mg/day.			Quantity: Refills:	
ADDECODIDED CLONATUE	E REQUIRED (S'	TAMP SIGNAT	URE NOT AL	LLOWED)		
PRESCRIBER SIGNATUR	"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution /					
			May Substitute / P Substitution Perm	Product Selection Pe issible	ermitted /	
				issible	ermitted /	Date:

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

Movement Disorders Enrollment Form

P				
Please Complete Patient and Prescriber information Patient DOB:Patient Phone:				
	Pre	escriber Phone:		
		DOCE C DIDECTIONS	OLIANITITY/DEFILLS	
Titration Kit ***	Administer 12 mg by mouth once a day during Week 1, 18 mg by mouth once a day during Week 2, 24 mg by mouth once a day during Week 3, and 30 mg by mouth once a day during Week 4 *** Titration Kit contents: (Weeks 1 and 2 Blister Pack contains seven 12 mg tablets taken during Week 1; and contains seven 6 mg tablets and seven 12 mg tablets taken during Week 2. Weeks 3 and 4 Blister Pack contains seven 24 mg tablets taken during Week 3; and contains seven 6 mg tablets and seven 24		QUANTITY/REFILLS Quantity: 1 kit Refills: 0	
☐ 6 mg ☐ 12 mg ☐ 24 mg ☐ 30 mg ☐ 36 mg ☐ 42 mg ☐ 48 mg	below: Administer 24 I Administer 30 I Administer 36 I Administer 42 I	mg by mouth once a day mg by mouth once a day mg by mouth once a day mg by mouth once a day	Quantity: Refills:	
☐ 50 mg			Quantity: Refills:	
☐ Initiation Pack *** ☐ 40 mg ☐ 60 mg ☐ 80 mg	increase the dose control symptoms per day.	Quantity: 30-day supply Refills: 0		
☐ 40 mg ☐ 60 mg ☐ 80 mg	Administer 40 Administer 60 Administer 80	mg by mouth once a day mg by mouth once a day	Quantity: Refills:	
☐ 40 mg ☐ 60 mg ☐ 80 mg	Administer 40 mg by mouth once a day. After one week increase the dose by 20 mg every two weeks as needed to control symptoms. Maximum daily dose not to exceed 80 mg per day.		Quantity: 30-day supply Refills: 0	
40 mg 60 mg 80 mg	☐ Administer 40 mg by mouth once a day ☐ Administer 60 mg by mouth once a day ☐ Administer 80 mg by mouth once a day ☐ Other		Quantity:Refills:	
. 3		· · · · · · · · · · · · · · · · · · ·	needed for administration	
lly Necessary / Do Not Substitute	e / No Substitution / _Date:	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:		
	Titration Kit *** 6 mg	DRMATION STRENGTH Administer 12 rby mouth once a cday during Week 3 week 4 Titration Kit *** *** Titration Kit coseven 12 mg table 6 mg tablets and 9 week 3; and 4 Blist during Week 3; and 12 mg below: 6 mg	Prescriber Phone: DOSE& DIRECTIONS	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and sub mit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates